初诊转移性鼻咽癌转移灶放疗在化疗免疫及局部放疗中的疗效
多中心回顾性研究纳入347例初诊转移性鼻咽癌患者,均接受≥2周期一线化疗免疫治疗及局部区域放疗,其中77例接受转移灶放疗。转移灶放疗组中位无进展生存期未达到,优于未放疗组的34.87个月(p=0.006);基于转移灶数量、肝转移及治疗后EBV DNA构建的RPA模型将患者分为低、中、高危组,仅低危组从转移灶放疗中显著获益。
要点
- 转移灶放疗组中位PFS未达到,优于未放疗组的34.87个月(p=0.006)。
- RPA模型低、中、高危组3年PFS率分别为71.4%、39.2%、12.3%。
- 仅低危组转移灶放疗显著改善3年PFS(82.8% vs. 69.1%,p=0.031)。
核心结论
- 转移灶放疗可使具有低危特征(转移灶数量有限、EBV DNA检测不到)的初诊转移性鼻咽癌患者获益。
- 基于转移负荷和EBV DNA状态的风险分层可指导免疫治疗时代的个体化转移灶放疗决策。
研究设计与样本
- 多中心回顾性研究,纳入4个中心的347例初诊转移性鼻咽癌患者。
- 所有患者接受≥2周期一线化疗免疫治疗及局部区域放疗,其中77例接受转移灶放疗。
- 采用Cox回归分析预后因素,并采用递归 partitioning 分析(RPA)构建风险分层预后模型。
主要发现
- 转移灶放疗组中位PFS未达到,非转移灶放疗组为34.87个月(p=0.006)。
- RPA模型基于转移灶数量、肝转移及治疗后EBV DNA将患者分为低、中、高危三组,3年PFS率分别为71.4%、39.2%、12.3%。
- 低危组中转移灶放疗显著改善3年PFS(82.8% vs. 69.1%,p=0.031),中危和高危组未见显著获益。
- 独立不良预后因素包括治疗后EBV DNA可检测到(HR=3.36)、肝转移(HR=1.5)及转移灶>5个(HR=1.52)。
关键数值与推荐
- 低危组3年PFS率71.4%,中危组39.2%,高危组12.3%。
- 低危组接受转移灶放疗者3年PFS率为82.8%,未接受者为69.1%(p=0.031)。
- 转移灶放疗组中位PFS未达到,非转移灶放疗组为34.87个月(p=0.006)。
临床怎么用
- 对初诊转移性鼻咽癌患者接受化疗免疫及局部区域放疗前,可依据转移灶数量、肝转移及治疗后EBV DNA进行风险分层。
- 低危特征患者(转移灶数量有限、EBV DNA检测不到)可考虑联合转移灶放疗以改善无进展生存。
- 中危和高危患者转移灶放疗未见显著PFS获益,决策需个体化权衡。
局限性
- 本研究为回顾性研究,转移灶放疗组仅77例,可能存在选择偏倚。
- 预后模型基于单次多中心数据构建,需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: De novo metastatic nasopharyngeal carcinoma (dmNPC) exhibits heterogeneous survival outcomes. While combining chemo-immunotherapy with locoregional radiotherapy (LRRT) improves outcomes, the role of metastatic lesion radiotherapy (MLRT) remains controversial, especially in the context of immunotherapy. This study aims to evaluate MLRT's efficacy in dmNPC patients receiving chemo-immunotherapy and LRRT and establish a prognostic model for identifying MLRT beneficiaries. MATERIALS AND METHODS: The study comprised of 347 dmNPC patients from four different centers. All patients received ≥2 cycles of first-line chemo-immunotherapy and LRRT. MLRT was administered to 77 patients. Prognostic factors were analyzed using Cox regression. A recursive partitioning analysis (RPA) model was employed to construct a prognostic model for risk stratification. Progression-free survival (PFS) differences between MLRT and non-MLRT groups were compared across risk strata. RESULTS: MLRT recipients demonstrated superior median PFS (not reached vs. 34.87 months, p = 0.006). The RPA model classified patients into three risk groups based on the number of metastatic lesions, liver metastasis, and post-treatment Epstein-Barr Virus (EBV) DNA. The 3-year PFS rates for the low-, medium-, and high-risk groups were 71.4 %, 39.2 %, and 12.3 %. MLRT significantly improved 3-year PFS in low-risk patients (82.8 % vs. 69.1 %, p = 0.031), but not in medium or high-risk groups. Independent adverse prognostic factors included detectable post-treatment EBV DNA (HR = 3.36), liver metastasis (HR = 1.5), and >5 metastatic lesions (HR = 1.52). CONCLUSION: MLRT benefits dmNPC patients with low-risk features (limited metastases, undetectable EBV DNA). Risk stratification using metastatic burden and EBV DNA status may guide personalized MLRT decisions in the immunotherapy era.
引用
- He SQ, Lv SH, Wen SQ, et al. Efficacy of metastatic lesion radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving local regional radiotherapy and chemo-immunotherapy: a multicenter retrospective study. Radiother Oncol. 2025. PMID: 40998268. doi:10.1016/j.radonc.2025.111160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。